BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 19487380)

  • 1. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.
    Poultsides GA; Servais EL; Saltz LB; Patil S; Kemeny NE; Guillem JG; Weiser M; Temple LK; Wong WD; Paty PB
    J Clin Oncol; 2009 Jul; 27(20):3379-84. PubMed ID: 19487380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
    Nitzkorski JR; Farma JM; Watson JC; Siripurapu V; Zhu F; Matteotti RS; Sigurdson ER
    Ann Surg Oncol; 2012 Feb; 19(2):379-83. PubMed ID: 21861213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
    J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of Surgical Resection of the Primary Tumor in Patients Undergoing Chemotherapy for Stage IV Colorectal Cancer with Unresected Metastasis.
    Maroney S; de Paz CC; Reeves ME; Garberoglio C; Raskin E; Senthil M; Namm JP; Solomon N
    J Gastrointest Surg; 2018 Mar; 22(3):460-466. PubMed ID: 29124549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical Resection of Primary Tumor in Asymptomatic or Minimally Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience.
    Ahmed S; Fields A; Pahwa P; Chandra-Kanthan S; Zaidi A; Le D; Haider K; Reeder B; Leis A
    Clin Colorectal Cancer; 2015 Dec; 14(4):e41-7. PubMed ID: 26140732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
    Miyamoto Y; Watanabe M; Sakamoto Y; Shigaki H; Murata A; Sugihara H; Etoh K; Ishimoto T; Iwatsuki M; Baba Y; Iwagami S; Yoshida N; Baba H
    Surg Today; 2014 Dec; 44(12):2287-92. PubMed ID: 24623012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
    Gervaz P; Rubbia-Brandt L; Andres A; Majno P; Roth A; Morel P; Mentha G
    Ann Surg Oncol; 2010 Oct; 17(10):2714-9. PubMed ID: 20405223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
    Kwon HC; Oh SY; Lee S; Kim SH; Kim HJ
    World J Gastroenterol; 2007 Dec; 13(46):6231-5. PubMed ID: 18069765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
    Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
    Cetin B; Kaplan MA; Berk V; Tufan G; Benekli M; Isikdogan A; Ozkan M; Coskun U; Buyukberber S
    Jpn J Clin Oncol; 2013 Jan; 43(1):28-32. PubMed ID: 23107836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
    Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonoperative management of primary colorectal cancer in patients with stage IV disease.
    Scoggins CR; Meszoely IM; Blanke CD; Beauchamp RD; Leach SD
    Ann Surg Oncol; 1999; 6(7):651-7. PubMed ID: 10560850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of unplanned surgery in patients with stage IV colorectal cancer receiving palliative chemotherapy with an intact primary: An analysis of SEER-Medicare.
    Lorimer PD; Motz BM; Kirks RC; Han Y; Symanowski JT; Hwang JJ; Salo JC; Hill JS
    J Surg Oncol; 2019 Sep; 120(3):407-414. PubMed ID: 31102466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.